| Index | — | P/E | — | EPS (ttm) | -1.86 | Insider Own | 7.89% | Shs Outstand | 149.64M | Perf Week | -1.26% |
| Market Cap | 1.06B | Forward P/E | — | EPS next Y | -2.32 | Insider Trans | 7.31% | Shs Float | 127.72M | Perf Month | -6.98% |
| Enterprise Value | 624.43M | PEG | — | EPS next Q | -0.55 | Short Float | 2.93% | Perf Quarter | -24.73% | ||
| Income | -242.00M | P/S | 21.56 | EPS this Y | — | Short Ratio | 5.52 | Perf Half Y | -36.62% | ||
| Sales | 49.00M | P/B | 2.32 | EPS next Y | — | ROA | -42.54% | Short Interest | 3.75M | Perf YTD | -32.76% |
| Book/sh | 3.05 | P/C | 2.35 | EPS next 5Y | — | ROE | -47.04% | 52W High | 12.41 -43.11% | Perf Year | -32.25% |
| Cash/sh | 3.00 | P/FCF | — | EPS past 3/5Y | — | ROIC | -52.53% | 52W Low | 6.65 6.17% | Perf 3Y | -9.49% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -33.30% 8.45% | Gross Margin | — | Volatility | 5.43% 5.66% | Perf 5Y | -45.65% |
| Dividend TTM | — | EV/Sales | 12.74 | EPS Y/Y TTM | — | Oper. Margin | -543.79% | ATR (14) | 0.43 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 7.54 | Sales Y/Y TTM | -65.25% | Profit Margin | -495.27% | RSI (14) | 39.32 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 7.54 | EPS Q/Q | 19.70% | SMA20 | -2.68% | Beta | 1.32 | Target Price | 17.00 |
| Payout | 0.00% | Debt/Eq | 0.04 | Sales Q/Q | 120.00% | SMA50 | -14.03% | Rel Volume | 1.24 | Prev Close | 7.20 |
| Employees | 704 | LT Debt/Eq | 0.03 | Earnings | Nov 17 | SMA200 | -26.27% | Avg Volume | 828.15K | Price | 7.06 |
| IPO Date | Dec 12, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 4.97% -14.15% | Net Debt/EBITDA | — | Volume | 1,023,170 | Change | -1.94% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-29-26 | Reiterated | Mizuho Securities | Outperform | $25 → $21 |
| Oct-13-26 | Initiated | Stifel | Buy | $15 |
| Aug-25-26 | Reiterated | Jefferies | Buy | $18 → $17 |
| Feb-19-26 | Reiterated | Mizuho Securities | Outperform | $23 → $25 |
| Dec-04-25 | Reiterated | Leerink Partners | $17 | |
| Oct-29-25 | Reiterated | Mizuho Securities | Buy | $16 → $19 |
| Sep-17-25 | Initiated | Guggenheim | Buy | $16 |
| May-16-24 | Reiterated | Mizuho | Buy | $16 |
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 49 | 54 | 169 | 58 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 49 | 54 | 169 | 58 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 64 | 58 | 50 | 41 | — | — | — | — | — | |
| Research and Development | 255 | 207 | 160 | 128 | — | — | — | — | — | |
| Other Operating Expense | -6 | -5 | 0 | -1 | — | — | — | — | — | |
| Operating Income | -264 | -205 | -42 | -110 | — | — | — | — | — | |
| Interest Expense | 0 | 1 | 1 | 1 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 24 | -17 | 66 | 6 | — | — | — | — | — | |
| Net Income Before Taxes | -241 | -224 | 23 | -105 | — | — | — | — | — | |
| Income Taxes | 0 | -2 | 7 | -3 | — | — | — | — | — | |
| Consolidated Net Income | -242 | -222 | 16 | -102 | — | — | — | — | — | |
| Net Income From Continuing Operations | -242 | -222 | 16 | -102 | — | — | — | — | — | |
| Net Income | -242 | -222 | 16 | -102 | — | — | — | — | — | |
| EPS (Recurring) | -1.86 | -1.74 | 0.15 | -1.28 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.86 | -1.74 | 0.15 | -1.28 | — | — | — | — | — | |
| EPS (Diluted) | -1.86 | -1.74 | 0.15 | -1.28 | — | — | — | — | — | |
| EBITDA | -225 | -209 | 37 | -96 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 46.94 | — | — | — | — | — | — | |
| Price To Sales Ratio | 19.74 | 23.72 | 4.50 | 14.71 | — | — | — | — | — | |
| Gross Margin | 100.00 | 100.00 | 100.00 | 100.00 | — | — | — | — | — | |
| Operating Margin | -538.78 | -379.63 | -24.85 | -189.66 | — | — | — | — | — | |
| Net Margin | -493.88 | -411.11 | 9.47 | -175.86 | — | — | — | — | — | |
| Shares Outstanding | 137 | 122 | 107 | 81 | — | — | — | — | — | |
| Market Capitalization | 967 | 1,281 | 761 | 853 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | Director | Aug 26 '26 | Buy | 8.69 | 863,060 | 7,499,991 | 11,246,516 | Aug 27 |